Pulmatrix M&A Deal with Eos SENOLYTIX, Inc.
Pulmatrix provided a status update on its pending merger with Eos SENOLYTIX, noting that the SEC has declared its Form S-4 registration statement effective and stockholders have approved the deal. The company expects the merger to close by the end of 2026, subject to Nasdaq listing approval and a planned reverse stock split.
- Counterparty
- Eos SENOLYTIX, Inc.
“Our focus in the third quarter and beyond has been to advance steps towards completing the proposed merger with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using the MitoXcel™ platform. To that end, we have obtained SEC effectiveness on our registration statement on Form S-4 in relation to the merger as well as approval from our stockholders on the proposed merger. We anticipate closing the proposed merger by the end of the year.”
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix